Abstract: Systems and methods for enhancing quantitative transfer of analytes to an adsorptive substrate are provided. A preferred embodiment provides an improved transfer system and method that reduces “blow through” of low molecular weight analytes and increases the adsorption of low molecular weight, for example proteins of about 30 kDa or less compared to conventional transfer techniques. It has been discovered that using a secondary porous backing membrane in conjunction with an adsorptive membrane such as nitrocellulose or polvinylidene fluoride increases the efficiency of analyte interaction with the adsorption membrane compared to transfers techniques using the adsorption membrane without the secondary backing membrane. This improvement of quantitative analyte transfer efficiency facilitates a wider range of detection processes, such as direct analysis by MALDI mass spectrometry than in earlier applications of the process without the secondary backing membrane.

Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active labile agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active labile agent incorporated therein, and a corticosteroid wherein the labile is released for a period of at least about two weeks. It is understood that the corticosteroid is present in an amount sufficient to modify the release profile of the biologically active labile agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.

Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.

Abstract: A heterodimeric form of TGF-.beta. is described. This 25 KD molecule is active in an in vitro assay of inhibition of epithelial cell growth. The protein may be isolated from bone. When reduced, the protein elutes in two peaks by RP-HPLC. In immunoblots, the reduced protein from the earlier eluting peak reacts predominately with antibodies directed against TGF-.beta.3, while reduced protein from the later eluting peak reacts predominately with antibodies directed against TGF-.beta.2. The N-terminal amino acid sequence and immunoreactivity of the native protein are consistent with a heterodimer of TGF-.beta.2 and TGF-.beta.3.